CorMedix, Inc. (CRMD)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$8.43-0.47%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · CRMD
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -84.4% |
| Our one-year growth estimate | diamond | -30.3% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 54.0 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name operates in a high-miss-rate industry and has been missing across recent quarters. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
CRMD — litigation filed
Dated 2026-08-07
Other Events. On July 24, 2026, the U.S. District Court for the District of New Jersey (the “District Court”) issued an order granting preliminary approval of the proposed settlement of the consolidated derivative lawsuit captioned In re CorMedix Inc. Derivative Litigation , Case No. 2:21-cv-18493-JXN-LDW (D.N.J) and a related shareholder derivative action captioned Raval v.Baluch , C.A. UNN-l-3721 (N.J. Super. Ct. Law. Div.). A final settlement hearing to consider the proposed settlement is…
Why it matters: The lawsuit outcome may change CorMedix's market position and revenue.
Worry ifThe court rules in favor of CorMedix, affirming its patents.
Less concerning ifThe court rules against CorMedix, weakening its patent claims.
Why it matters: Good trial results could help REZZAYO get approved and accepted in the market.
Watch forFDA reviews the REZZAYO sNDA favorably based on positive Phase III results.
Also watch forFDA raises concerns about the Phase III trial results affecting the sNDA review.
Why it matters: Confirming or raising revenue guidance shows strong demand. It builds investor confidence.
Supportive ifThe company keeps or raises full-year 2026 revenue guidance over $325 million.
Worry ifThe company cuts its revenue forecast for 2026 to below $325 million.
Why it matters: Sales trends for DefenCath are crucial for revenue growth. A decline could signal issues with market demand or competition.
Worry ifDefenCath sales growth is slowing down. It may even drop compared to past quarters.
Less concerning ifDefenCath sales continue to grow or stabilize at previous levels.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$173 on $10,000 · ±1.7% | How much price usually moves either way. |
| Bad day | $501 loss on $10,000 · 5.0% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $5,225 loss on $10,000 · 52.3% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Patent updates may affect MINOCIN's market position. Strong IP protection helps keep revenue stable.
Supportive ifCorMedix announces new legal actions or settlements. These will help the MINOCIN patent.
Worry ifIf legal challenges to MINOCIN patents win, or if new generic drugs come out.
Why it matters: The FDA submission is key for expanding REZZAYO's market potential. Success could lead to increased revenue.
Supportive ifThe company submits the sNDA for REZZAYO. This is for preventing invasive fungal disease.
Worry ifThe company delays the sNDA submission beyond Q3 2026.
Why it matters: DefenCath sales are growing. This shows strong demand and helps revenue plans for the year.
Supportive ifDefenCath sales in Q3 2026 exceed $66.1 million.
Worry ifDefenCath sales in Q3 2026 fall below $60 million.
Why it matters: The result could change how management uses its focus and resources. It may also change how investors feel and how the stock does.
Watch forThe court approves the proposed settlement of the lawsuit.
Also watch forThe court rejects the proposed settlement or there are big objections.